Cyclosporine and Prednisolone as First-line Treatment of Subcutaneous Panniculitis-like T Cell Lymphoma: Clinical Features and Outcomes in 4 Patients
Keywords:
Subcutaneous panniculitis-like T cell lymphoma, Cyclosporine, PrednisoloneAbstract
Background: Subcutaneous panniculitis-like T-cell lymphoma (SPTCL) is a rare primary cutaneous T-cell lymphoma that can present with subcutaneous nodules mimicking panniculitis. Treatment protocols for SPTCL are varied, due to lack of agreement on standard treatment. Recent publications showed good response to treatment with cyclosporine and/or prednisolone as first-line treatment for SPTCL.
Objective: We aimed to study the outcome of SPTCL patients treated using cyclosporine and prednisolone as a first-line treatment, and also describe clinical presentations, histopathology, immunophenotype, molecular, treatment protocol, and treatment outcomes.
Results: Our study reported 4 SPTCL patients that presented with multiple subcutaneous nodules or indurated plaques, associated with fever and weight loss. All patients received cyclosporine and prednisolone as first-line treatment and achieved complete remission within 4-8 weeks. Three patients are still in complete remission. Relapse of SPTCL was suspected in one patient.
Conclusion: Our results suggest that cyclosporine and prednisolone are beneficial and could be use as first-line treatment in SPTCL.
References
Willemze R, Jansen PM, Cerroni L, et al. Subcutaneous panniculitis-like T-cell lymphoma: Definition, classification, and prognostic factors: An EORTC Cutaneous Lymphoma Group Study of 83 cases. Blood. 2008; 111 (2): 838-45.
Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003; 148 (3): 516–25.
Rojnuckarin P, Nakorn TN, Assanasen T, et al. Cyclosporin in subcutaneous panniculitis-like T-cell lymphoma. Leuk Lymphoma. 2007; 48 (3): 560–3.
Gonzalez CL, Medeiros LJ, Braziel RM, et al. T-cell lymphoma involving subcutaneous tissue. A clinicopathologic entity commonly associated with hemophagocytic syndrome. Am J Surg Pathol. 1991; 15 (1): 17–27.
Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105 (10): 3768–85.
Swerdlow SH, Campo E, Harris N, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. 4thed. Vol. 2. Lyon: IARC. 2008. p. 294-95.
López-Lerma I, Peñate Y, Gallardo F, et al. Subcutaneous panniculitis-like T-cell lymphoma: Clinical features, therapeutic approach, and outcome in a case series of 16 patients. J Am Acad Dermatol. 2018; 79 (5): 892–8.
Tsukamoto Y, Katsunobu Y, Omura Y, et al. Subcutaneous panniculitis-like T-cell lymphoma: successful initial treatment with prednisolone and cyclosporin A. Intern Med. 2006; 45 (1): 21–4.
Lee WS, Hwang J-H, Kim MJ, et al. Cyclosporine A as a Primary Treatment for Panniculitis-like T Cell Lymphoma: A Case with a Long-Term Remission. Cancer Res Treat. 2014; 46 (3): 312–6.
Aragón-Miguel R, Calleja-Algarra A, Velasco-Tamariz V, et al. Is cyclosporine a good option for the treatment of subcutaneous panniculitis-like T-cell lymphoma associated with hemophagocytic syndrome? Indian J Dermatol Venereol Leprol. 2019; 85 (6): 656–9.
Iqbal N, Raina V. Successful treatment of disseminated subcutaneous panniculitis-like T-cell lymphoma with single agent oral cyclosporine as a first line therapy. Case Rep Dermatol Med. 2014; 2014: 201836.
Michonneau D, Petrella T, Ortonne N, et al. Subcutaneous Panniculitis-like T-cell Lymphoma: Immunosuppressive Drugs Induce Better Response than Polychemotherapy. Acta Derm Venereol. 2017; 97 (3): 358–64.
Ohtsuka M, Miura T, Yamamoto T. Clinical characteristics, differential diagnosis, and treatment outcome of subcutaneous panniculitis-like T-cell lymphoma: a literature review of published Japanese cases. Eur J Dermatol. 2017; 27 (1): 34–41.
Mitsuhashi K, Momose M, Masuda A, et al. Positron emission tomography revealed diffuse involvement of the lower legs and occult extracutaneous lesions in subcutaneous panniculitislike T-cell lymphoma. Clin Nucl Med. 2013; 38 (3): 209–11.
Lester L, Ewalt M, Warnke R, et al. Systemic panniculitis-like T-cell lymphoma with involvement of mesenteric fat and subcutis. J Cutan Pathol. 2015; 42 (1): 46–9.
Lee D-W, Yang J-H, Lee S-M, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinical and pathologic study of 14 Korean patients. Ann Dermatol. 2011; 23 (3): 329–37.
Gilson D, Whittaker SJ, Child FJ, et al. British Association of Dermatologists and U.K. Cutaneous Lymphoma Group guidelines for the management of primary cutaneous lymphomas 2018. Br J Dermatol. 2019; 180 (3): 496–526.
Willemze R, Hodak E, Zinzani PL, et al. Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018; 29 (Suppl 4): iv30–40.
Ohtsuka M, Hamada T, Miyagaki T, et al. Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020. J Dermatol. 2021; 48 (2): e49-e71.
